Receive our newsletter – data, insights and analysis delivered to you
  1. News
April 28, 2016

Shockwave Medical reports positive data from pooled DISRUPT PAD study for lithoplasty technology

US-based developer of lithoplasty technology, Shockwave Medical has reported positive results from the pooled DISRUPT PAD study while assessing the safety and performance of Lithoplasty System to treat peripheral artery disease.

US-based developer of lithoplasty technology, Shockwave Medical has reported positive results from the pooled DISRUPT PAD study while assessing the safety and performance of Lithoplasty System to treat peripheral artery disease.

The single-arm, two-phase multicentre study involved eight sites and 95 patients with calcified vascular stenosis of the superficial femoral artery (SFA) and popliteal artery, who were examined by Universitäts-Herzzentrum Freiburg-Bad Krozingen angiology department head Thomas Zeller.

The results are said to have demonstrated a safe and successful treatment of patients with calcified peripheral artery disease leveraging on lithoplasty technology.

"The positive results of the DISRUPT PAD programme reinforce our belief that the Lithoplasty System is uniquely suited to address substantial unmet needs in the treatment of patients."

Primary efficacy results exhibited 100% acute success, defined as the ability to achieve less than 50% residual stenosis using lithoplasty with or without adjunctive angioplasty.

Shockwave Medical CEO and co-founder Daniel Hawkins said: "The positive results of the DISRUPT PAD programme reinforce our belief that the Lithoplasty System is uniquely suited to address substantial unmet needs in the treatment of patients with peripheral, coronary and heart valve disease, using a balloon-based approach that is inherently familiar to physicians."

The Lithoplasty technology combines the calcium-disrupting power of lithotripsy with simple balloon-based interventional devices, using the integrated lithotripsy emitters to issue mechanical pulse waves to disrupt both superficial and deep calcium. This normalises vessel wall compliance prior to low-pressure balloon dilatation.

Content from our partners
“Everything is custom”: Behind the scenes of medical wire solutions
The added value of Qarad’s multilingual freephone service to their eIFU solution
Small and simple: how medical device manufacturers select materials

It is said to target only the superficial calcium without affecting deep calcium, causing reduced soft tissue injury and restoring blood flow.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU